MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 406771 | Name: AIM-100
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

AIM-100 is a potent and selective Ack1 tyrosine kinase with IC50 value of 24 nM. AIM-100, not only inhibited Ack1 activation but also able to suppress pTyr267-AR phosphorylation, binding of AR to PSA, NKX3.1, and TMPRSS2 promoters, and inhibit AR transcription activity. Ack1 tyrosine kinase activation correlates with pancreatic cancer progression. Ack1 inhibitors hold promise for therapeutic intervention to inhibit pancreatic tumor growth.

Chemical Structure

AIM-100
AIM-100
CAS#873305-35-2

Theoretical Analysis

MedKoo Cat#: 406771

Name: AIM-100

CAS#: 873305-35-2

Chemical Formula: C23H21N3O2

Exact Mass: 371.1634

Molecular Weight: 371.44

Elemental Analysis: C, 74.37; H, 5.70; N, 11.31; O, 8.61

Price and Availability

Size Price Availability Quantity
50mg USD 450.00 2 Weeks
100mg USD 750.00 2 Weeks
200mg USD 1,250.00 2 Weeks
500mg USD 2,450.00 2 Weeks
1g USD 3,850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
AIM-100; AIM 100; AIM100.
IUPAC/Chemical Name
N-[[(2S)-oxolan-2-yl]methyl]-5,6-diphenylfuro[2,3-d]pyrimidin-4-amine
InChi Key
XNFHHOXCDUAYSR-SFHVURJKSA-N
InChi Code
InChI=1S/C23H21N3O2/c1-3-8-16(9-4-1)19-20-22(24-14-18-12-7-13-27-18)25-15-26-23(20)28-21(19)17-10-5-2-6-11-17/h1-6,8-11,15,18H,7,12-14H2,(H,24,25,26)/t18-/m0/s1
SMILES Code
C12=NC=NC(NC[C@H]3OCCC3)=C1C(C4=CC=CC=C4)=C(C5=CC=CC=C5)O2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 371.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Cheng MH, Ponzoni L, Sorkina T, Lee JY, Zhang S, Sorkin A, Bahar I. Trimerization of dopamine transporter triggered by AIM-100 binding: Molecular mechanism and effect of mutations. Neuropharmacology. 2019 Dec 15;161:107676. doi: 10.1016/j.neuropharm.2019.107676. Epub 2019 Jun 20. PMID: 31228486; PMCID: PMC6917874. 2: Sorkina T, Ma S, Larsen MB, Watkins SC, Sorkin A. Small molecule induced oligomerization, clustering and clathrin-independent endocytosis of the dopamine transporter. Elife. 2018 Apr 9;7:e32293. doi: 10.7554/eLife.32293. PMID: 29630493; PMCID: PMC5896956. 3: Zhou A, Zhang W, Wang B. Host factor TNK2 is required for influenza virus infection. Genes Genomics. 2023 Jun;45(6):771-781. doi: 10.1007/s13258-023-01384-8. Epub 2023 May 3. PMID: 37133719. 4: Wang B, Song K, Chen L, Su H, Gao L, Liu J, Huang A. Targeted inhibition of ACK1 can inhibit the proliferation of hepatocellular carcinoma cells through the PTEN/AKT/mTOR pathway. Cell Biochem Funct. 2020 Jul;38(5):642-650. doi: 10.1002/cbf.3522. Epub 2020 Mar 12. PMID: 32162707. 5: Jing L, Zhang X, Liu D, Yang Y, Xiong H, Dong G. ACK1 Contributes to the Pathogenesis of Inflammation and Autoimmunity by Promoting the Activation of TLR Signaling Pathways. Front Immunol. 2022 May 20;13:864995. doi: 10.3389/fimmu.2022.864995. PMID: 35669783; PMCID: PMC9164107. 6: Amigo N, Palominos S, Valencia FJ. Machine learning modeling for the prediction of plastic properties in metallic glasses. Sci Rep. 2023 Jan 7;13(1):348. doi: 10.1038/s41598-023-27644-x. PMID: 36611063; PMCID: PMC9825623. 7: Mahajan K, Coppola D, Rawal B, Chen YA, Lawrence HR, Engelman RW, Lawrence NJ, Mahajan NP. Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer. J Biol Chem. 2012 Jun 22;287(26):22112-22. doi: 10.1074/jbc.M112.357384. Epub 2012 May 7. PMID: 22566699; PMCID: PMC3381169. 8: Mahajan K, Challa S, Coppola D, Lawrence H, Luo Y, Gevariya H, Zhu W, Chen YA, Lawrence NJ, Mahajan NP. Effect of Ack1 tyrosine kinase inhibitor on ligand- independent androgen receptor activity. Prostate. 2010 Sep 1;70(12):1274-85. doi: 10.1002/pros.21163. PMID: 20623637; PMCID: PMC3953126. 9: Nourse JB Jr, Russell SN, Moniz NA, Peter K, Seyfarth LM, Scott M, Park HA, Caldwell KA, Caldwell GA. Integrated regulation of dopaminergic and epigenetic effectors of neuroprotection in Parkinson's disease models. Proc Natl Acad Sci U S A. 2023 Feb 14;120(7):e2210712120. doi: 10.1073/pnas.2210712120. Epub 2023 Feb 6. PMID: 36745808; PMCID: PMC9963946. 10: Mahajan K, Lawrence HR, Lawrence NJ, Mahajan NP. ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1. J Biol Chem. 2014 Oct 10;289(41):28179-91. doi: 10.1074/jbc.M114.584425. Epub 2014 Aug 22. PMID: 25148682; PMCID: PMC4192474. 11: He W, Xu L, Ding J, Song L, Yang W, Klooster I, Pilco-Janeta DF, Serrano C, Fang H, Jiang G, Wang X, Yu J, Ou WB. Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors. Biochim Biophys Acta Mol Basis Dis. 2023 Jun;1869(5):166690. doi: 10.1016/j.bbadis.2023.166690. Epub 2023 Mar 13. PMID: 36921738. 12: Mahajan K, Coppola D, Chen YA, Zhu W, Lawrence HR, Lawrence NJ, Mahajan NP. Ack1 tyrosine kinase activation correlates with pancreatic cancer progression. Am J Pathol. 2012 Apr;180(4):1386-93. doi: 10.1016/j.ajpath.2011.12.028. Epub 2012 Feb 7. PMID: 22322295; PMCID: PMC3349895. 13: Zhu J, Cao K, Zhao M, Ma K, Jiang X, Bai Y, Ling X, Ma J. Improvement of ACK1-targeted therapy efficacy in lung adenocarcinoma using chloroquine or bafilomycin A1. Mol Med. 2023 Jan 16;29(1):6. doi: 10.1186/s10020-023-00602-z. PMID: 36647009; PMCID: PMC9843944. 14: Hensler M, Paul S, Abright C, Lorenzl S. Progressive supranukleäre Blickparese : Lebensumstände der Patienten in Deutschland [Progressive supranuclear palsy: living environment of the patients in Germany]. Nervenarzt. 2011 Feb;82(2):207-14. German. doi: 10.1007/s00115-010-3076-7. PMID: 20669002. 15: Thaker YR, Recino A, Raab M, Jabeen A, Wallberg M, Fernandez N, Rudd CE. Activated Cdc42-associated kinase 1 (ACK1) binds the sterile α motif (SAM) domain of the adaptor SLP-76 and phosphorylates proximal tyrosines. J Biol Chem. 2017 Apr 14;292(15):6281-6290. doi: 10.1074/jbc.M116.759555. Epub 2017 Feb 10. PMID: 28188290; PMCID: PMC5391757.